Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
NCT01605318
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
92
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Colorectal Cancer
Colon Cancer
Rectal Cancer
Interventions
DRUG:
Labetuzumab Govitecan (LG)
Sponsor
Gilead Sciences